Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators.

N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.

2.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).

Lancet Oncol. 2012 Sep;13(9):916-26. Epub 2012 Aug 8.

PMID:
22877848
3.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.

N Engl J Med. 2005 Mar 10;352(10):987-96.

4.

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T.

N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.

5.

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.

Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M.

Cancer. 2009 Aug 1;115(15):3512-8. doi: 10.1002/cncr.24406.

6.

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.

Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.

PMID:
19269895
7.

Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma.

Muni R, Minniti G, Lanzetta G, Caporello P, Frati A, Enrici MM, Marchetti P, Enrici RM.

Tumori. 2010 Jan-Feb;96(1):60-4.

PMID:
20437859
8.

Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.

Daróczi B, Szántó E, Tóth J, Barzó P, Bognár L, Bakó G, Szántó J, Mózes P, Hideghéty K.

Ideggyogy Sz. 2013 Nov 30;66(11-12):391-8.

PMID:
24555238
9.

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society.

Lancet Oncol. 2012 Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10.

10.

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R.

Lancet Oncol. 2008 Jan;9(1):29-38. Epub 2007 Dec 21.

PMID:
18082451
11.

Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).

Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A, D'Avella D, Berti F, Rudà R, Zagonel V.

J Neurooncol. 2015 Nov;125(2):359-67. doi: 10.1007/s11060-015-1923-x. Epub 2015 Sep 30.

PMID:
26423801
12.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team.

Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.

13.
14.

Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.

van Genugten JA, Leffers P, Baumert BG, Tjon-A-Fat H, Twijnstra A.

J Neurooncol. 2010 Jan;96(2):249-57. doi: 10.1007/s11060-009-9956-7. Epub 2009 Jul 7.

15.

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z.

JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. Erratum in: JAMA. 2018 May 1;319(17):1824.

16.

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z.

JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.

17.

The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.

Park CK, Lee SH, Kim TM, Choi SH, Park SH, Heo DS, Kim IH, Jung HW.

J Neurooncol. 2013 Apr;112(2):277-83. doi: 10.1007/s11060-013-1060-3. Epub 2013 Feb 2.

PMID:
23377829
18.

Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.

Yang LJ, Zhou CF, Lin ZX.

Cancer Invest. 2014 Feb;32(2):31-6. doi: 10.3109/07357907.2013.861474. Epub 2013 Dec 14. Review.

PMID:
24328555
19.

Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.

Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, Michiara M, Servadei F, Pavesi G, Urbini B, Pisanello A, Crisi G, Cavallo MA, Dazzi C, Biasini C, Bertolini F, Mucciarini C, Pasini G, Baruzzi A, Brandes AA; PERNO Study Group.

J Neurooncol. 2016 May;128(1):157-162. doi: 10.1007/s11060-016-2093-1. Epub 2016 Mar 4. Erratum in: J Neurooncol. 2018 Jan;136(1):221-222.

PMID:
26943851
20.

Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.

Biau J, Chautard E, De Schlichting E, Dupic G, Pereira B, Fogli A, Müller-Barthélémy M, Dalloz P, Khalil T, Dillies AF, Durando X, Godfraind C, Verrelle P.

Radiat Oncol. 2017 Dec 6;12(1):197. doi: 10.1186/s13014-017-0929-2.

Supplemental Content

Support Center